125 related articles for article (PubMed ID: 23676009)
21. Design, synthesis and biological evaluation of novel naphthoquinone-4-aminobenzensulfonamide/carboxamide derivatives as proteasome inhibitors.
Uysal S; Soyer Z; Saylam M; Tarikogullari AH; Yilmaz S; Kirmizibayrak PB
Eur J Med Chem; 2021 Jan; 209():112890. PubMed ID: 33039723
[TBL] [Abstract][Full Text] [Related]
22. Discovery of Immunoproteasome Inhibitors Using Large-Scale Covalent Virtual Screening.
Scarpino A; Bajusz D; Proj M; Gobec M; Sosič I; Gobec S; Ferenczy GG; Keserű GM
Molecules; 2019 Jul; 24(14):. PubMed ID: 31315311
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and biological evaluation of novel non-covalent piperidine-containing peptidyl proteasome inhibitors.
Zhang J; Gao L; Xi J; Sheng L; Zhao Y; Xu L; Shao Y; Liu S; Zhuang R; Zhou Y; Li J
Bioorg Med Chem; 2016 Dec; 24(23):6206-6214. PubMed ID: 27765408
[TBL] [Abstract][Full Text] [Related]
24. Synthesis, in vitro and in vivo biological evaluation, docking studies, and structure--activity relationship (SAR) discussion of dipeptidyl boronic acid proteasome inhibitors composed of beta-amino acids.
Zhu Y; Zhu X; Wu G; Ma Y; Li Y; Zhao X; Yuan Y; Yang J; Yu S; Shao F; Li R; Ke Y; Lu A; Liu Z; Zhang L
J Med Chem; 2010 Mar; 53(5):1990-9. PubMed ID: 20158184
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of boronic acid derivatives of tyropeptin: proteasome inhibitors.
Watanabe T; Momose I; Abe M; Abe H; Sawa R; Umezawa Y; Ikeda D; Takahashi Y; Akamatsu Y
Bioorg Med Chem Lett; 2009 Apr; 19(8):2343-5. PubMed ID: 19307118
[TBL] [Abstract][Full Text] [Related]
26. A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome.
Achanta G; Modzelewska A; Feng L; Khan SR; Huang P
Mol Pharmacol; 2006 Jul; 70(1):426-33. PubMed ID: 16636137
[TBL] [Abstract][Full Text] [Related]
27. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
Berkers CR; Leestemaker Y; Schuurman KG; Ruggeri B; Jones-Bolin S; Williams M; Ovaa H
Mol Pharm; 2012 May; 9(5):1126-35. PubMed ID: 22432738
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
Suzuki N; Suzuki T; Ota Y; Nakano T; Kurihara M; Okuda H; Yamori T; Tsumoto H; Nakagawa H; Miyata N
J Med Chem; 2009 May; 52(9):2909-22. PubMed ID: 19419205
[TBL] [Abstract][Full Text] [Related]
29. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.
Troiano V; Scarbaci K; Ettari R; Micale N; Cerchia C; Pinto A; Schirmeister T; Novellino E; Grasso S; Lavecchia A; Zappalà M
Eur J Med Chem; 2014 Aug; 83():1-14. PubMed ID: 24946214
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors.
Yang Y; Wang K; Wu B; Yang Y; Lai F; Chen X; Xiao Z
Bioorg Med Chem Lett; 2020 Nov; 30(21):127508. PubMed ID: 32853683
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, biological evaluation, and structure-activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part I: comprehensive understanding of the SAR of alpha-amino acid boronates.
Zhu Y; Zhao X; Zhu X; Wu G; Li Y; Ma Y; Yuan Y; Yang J; Hu Y; Ai L; Gao Q
J Med Chem; 2009 Jul; 52(14):4192-9. PubMed ID: 19537716
[TBL] [Abstract][Full Text] [Related]
32. Structure-activity relationship for aryl and heteroaryl boronic acid inhibitors of hormone-sensitive lipase.
Ebdrup S; Jacobsen P; Farrington AD; Vedsø P
Bioorg Med Chem; 2005 Mar; 13(6):2305-12. PubMed ID: 15727879
[TBL] [Abstract][Full Text] [Related]
33. Design and discovery of novel dipeptide boronic acid ester proteasome inhibitors, an oral slowly-released prodrug for the treatment of multiple myeloma.
Wang X; Zhang W; Wen T; Miao H; Hu W; Liu H; Lei M; Zhu Y
Eur J Med Chem; 2023 Mar; 250():115187. PubMed ID: 36806958
[TBL] [Abstract][Full Text] [Related]
34. Naphthoquinone amino acid derivatives, synthesis and biological activity as proteasome inhibitors.
Marastoni M; Trapella C; Scotti A; Fantinati A; Ferretti V; Marzola E; Eleonora G; Gavioli R; Preti D
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):865-877. PubMed ID: 28657369
[TBL] [Abstract][Full Text] [Related]
35. Design, Synthesis, and Biological Activity of Isosyringolin A.
Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S
Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978
[TBL] [Abstract][Full Text] [Related]
36. Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
Zhao Y; Xu L; Zhang J; Zhang M; Lu J; He R; Xi J; Zhuang R; Li J; Zhou Y
Bioorg Med Chem; 2021 Jan; 29():115867. PubMed ID: 33223460
[TBL] [Abstract][Full Text] [Related]
37. Merging the Versatile Functionalities of Boronic Acid with Peptides.
Tan Y; Wu J; Song L; Zhang M; Hipolito CJ; Wu C; Wang S; Zhang Y; Yin Y
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884766
[TBL] [Abstract][Full Text] [Related]
38. Structure-activity relationship of boronic acid derivatives of tyropeptin: proteasome inhibitors.
Watanabe T; Abe H; Momose I; Takahashi Y; Ikeda D; Akamatsu Y
Bioorg Med Chem Lett; 2010 Oct; 20(19):5839-42. PubMed ID: 20727746
[TBL] [Abstract][Full Text] [Related]
39. Proteasome inhibitors with photocontrolled activity.
Hansen MJ; Velema WA; de Bruin G; Overkleeft HS; Szymanski W; Feringa BL
Chembiochem; 2014 Sep; 15(14):2053-7. PubMed ID: 25125335
[TBL] [Abstract][Full Text] [Related]
40. Development of novel proteasome inhibitors based on phthalazinone scaffold.
Yang L; Wang W; Sun Q; Xu F; Niu Y; Wang C; Liang L; Xu P
Bioorg Med Chem Lett; 2016 Jun; 26(12):2801-2805. PubMed ID: 27158142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
